威尼斯彩票登陆

    <small id="ecbcc"><label id="ecbcc"></label></small>

          <section id="ecbcc"></section><datalist id="ecbcc"></datalist><embed id="ecbcc"><samp id="ecbcc"><div id="ecbcc"></div><address id="ecbcc"></address></samp></embed><sup id="ecbcc"><map id="ecbcc"></map></sup><div id="ecbcc"></div><audio id="ecbcc"><sub id="ecbcc"><mark id="ecbcc"><thead id="ecbcc"></thead><small id="ecbcc"></small></mark></sub></audio><button id="ecbcc"></button>
            <tfoot id="ecbcc"><legend id="ecbcc"><abbr id="ecbcc"><output id="ecbcc"></output><li id="ecbcc"></li></abbr></legend><embed id="ecbcc"></embed><li id="ecbcc"></li></tfoot>

              Detection of lung adenocarcinoma with ROSI rearrangement by IHC,FISH,and RT-PCR and analysis of its clinicopathologic features
              Bing cao, Ping Wei, Zebing liu, et al.

              To detect  ROS1  rearrangement  using  three  different  assays,  including  immunohistochemistry (IHC), fluorescence in situ
              hybridization (FISH), and reverse transcription  polymerase chain reaction (RT-PCR), and to analyze the clinicopathologic
              features of ROS1 rearrangement in patients with lung adenocarcinoma.

              OncoTargets and Therapy, 2016:9 131-138

              非小细胞肺癌组织中ALK、ROS1和RET融合基因的表达及其临床意义
              钟山,张海萍,白冬雨等

              探讨非小细胞肺癌组织中ALK、ROS1和RET融合基因的表达情况及其与临床病理特征的关系。
               

              中华病理学杂志 2015年9月第44卷第9期(Chin J Pathol, September 2015 .Vol.44, No.9)

              非小细胞肺癌患者EML4-ALK融合基因突变研究
              王旭洲,陈炜生,余英豪

              非小细胞肺癌(non-small cell lung cancer, NSCLC)是肺癌的主要类型,相关位点突变检 测研究已经成为肺癌分子靶向治疗的热门方向,研究NSCLC肿瘤组织中动物微管相关蛋白4与间变性淋巴瘤激酶融合基因(echinodem microtubule associated protein like 4-
              Anaplastic lymphoma kinase, EML4-ALK)与表皮生长因子受体(epidermal growth factor receptor, EGFR)的基因突变状态,比较免疫组织化学(immunohistochemistry, IHC)与蝎形探针扩增阻滞突变系统(Scorpions amplification refractory mutation system, Scorpions ARMS)荧光定量PCR与荧光原位杂交(fluorescence in situ hybridization, FISH)检测EML4-ALK融合基因与EGFR基因突变的敏感性。

              中国肺癌杂志 2015年2月第18卷第2期(Chin J Lung Cancer, February 2015, Vol.18, No.2)

              Molecular spectrum of KRAS,NRAS,BRAF and PIK3CA mutations in Chinese colorectal cancer patients_analysis of 1,110 cases
              Jing Zhang, Jianming Zheng, Yinghong Yang, et al.

              Mutations in genes such as KRAS, NRAS, BRAF and PIK3CA have become an important part of colorectal carcinoma evaluation. The aim of this study was to screen for mutations in these genes in Chinese patients with colorectal cancer (CRC) and to
              explore their correlations with certain clinicopathological parameters. We tested mutations in the KRAS (exons 2, 3 and 4),
              NRAS (exons 2, 3 and 4), PIK3CA (exon 20) and BRAF (exon 15) genes using reverse transcriptase-polymerase chain reaction
              (RT-PCR) and Sanger sequencing in a large cohort of 1,110 Chinese CRC patients who underwent surgical resection at one of
              three major teaching hospitals located in different regions of China.

              Scientific RepoRts | 22 December 2015 | 5:18678 | DOI: 10.1038/srep18678

              Value of TIRADS, BSRTC and FNA-BRAFV600E mutation analysis in differentiating high-risk thyroid nodules(Scientific Reports)
              Yu-zhi Zhang, Ting Xu, Dai Cui, et al.

              The thyroid imaging reporting and data system (TIRADS) and Bethesda system for reporting thyroid cytopathology (BSRTC)
              have been used for interpretation of ultrasound and fine-needle aspiration cytology (FNAC) results of thyroid nodules.
              BRAFV 600E mutation analysis is a molecular tool in diagnosing thyroid carcinoma. Our objective was to compare the
              diagnostic value of these methods in differentiating high-risk thyroid nodules. Total 220 patients with high-risk thyroid
              nodules were recruited in this prospective study.

              Scientific Reports | 24 November 2015 | 5:16927 | DOI: 10.1038/srep16927

              Intratumoral Heterogeneity of ALK-Rearranged and ALK/EGFR Coaltered Lung Adenocarcinoma
              Weijing Cai, Dongmei Lin, Chunyan Wu, et al.

              Genetic intratumoral heterogeneity has a profound influence on the selection of clinical treatment strategies and on
              addressing resistance to targeted therapy. The purpose of this study was to explore the potential effect of intratumoral
              heterogeneity on both genetic and pathologic characteristics of ALK-rearranged lung adenocarcinoma (LADC).

              J Clin Oncol. 2015 November 10; 33(32): 3701–3709. doi:10.1200/JCO.2014.58.8293.